| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | 0.26 | 4e-12 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.19 | 3e-08 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-07 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-07 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | -0.17 | 2e-06 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-06 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 6e-06 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.24 | 7e-06 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.15 | 1e-05 |
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | -0.15 | 3e-05 |